Aragen Life Sciences has inaugurated its 'Aragen OneHP' facility in Hyderabad, a 15,000-square-foot plant designed to manufacture high-potency drugs like oncology treatments. This expansion follows a Rs 1,000 crore capital investment program completed in March 2026. As the company proceeds with its IPO plans, this facility marks a key step in its strategy to manage the full drug development cycle.
Aragen Life Sciences has officially launched its new high-potency development and manufacturing platform, branded as Aragen OneHP, at its Nacharam campus in Hyderabad. The 15,000-square-foot facility is built to handle sensitive compounds, including cytotoxic payloads used in oncology treatments, with an annual manufacturing capacity of 500 to 600 kg. By centralizing discovery, process development, and manufacturing, the company aims to help global clients move drugs from early-stage research to commercial scale without the need for complex handoffs between different service providers.
This launch is a direct result of the company’s broader capital spending program, which saw over Rs 1,000 crore deployed across projects over the three years ending in March 2026. The investment is intended to boost the company's capabilities in the contract development and manufacturing organization (CDMO) sector, where it competes to provide specialized drug manufacturing services to global pharmaceutical companies.
For those tracking the company’s progress, its financial performance provides important context. According to the Draft Red Herring Prospectus (DRHP) filed in August 2026, the company reported an operating revenue of Rs 2,178 crore for the financial year ending in March 2026. During the same period, it recorded an adjusted EBITDA of Rs 593 crore and a net profit of Rs 283 crore.
While the expansion highlights growth, the company’s business model carries specific risks that investors should understand. The firm has a high dependence on international markets, with over 90% of its revenue coming from outside India. This geographic concentration, particularly in the United States and Europe, makes the business susceptible to economic slowdowns, currency fluctuations, and changes in regulatory policies in those specific regions. Additionally, as a CDMO, the company must maintain strict control over intellectual property. Any failure to protect sensitive client information could have a significant impact on its reputation and future business.
Furthermore, the sector is highly competitive, with numerous players in India, China, and Eastern Europe vying for similar contracts. Success in this new facility will depend on the company's ability to maintain its scientific workforce and execute the complex manufacturing of potent molecules effectively. As the company moves forward with its IPO plans, the progress of this facility and its ability to secure new high-value contracts will be important developments for observers to follow.